Stille

Stille FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Stille (STIL.ST) as of Oct 24, 2026 is 27.76 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 101.77 % — a change of -72.73% (lower).

FCF Conversion

27.76 %

YoY

-72.73%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Stille is 2025 27.76 % . FCF Conversion Rate (FCF/EBITDA) of Stille was 2024 101.77 % . It decreases by -72.73% lower compared to the previous year.

The Stille FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
44.51 SEK
Jan 1, 2019
78.39 SEK
Jan 1, 2020
-34.91 SEK
Jan 1, 2021
-72.96 SEK
Jan 1, 2022
87.45 SEK
Jan 1, 2023
91.47 SEK
Jan 1, 2024
101.77 SEK
Jan 1, 2025
27.76 SEK
The Stille FCF Conversion history
YEARFCF ConversionYoY
27.76 %-72.73%
101.77 %+11.26%
91.47 %+4.60%
87.45 %-219.86%
-72.96 %+109.00%
-34.91 %-144.53%
78.39 %+76.11%
44.51 %-63.36%
121.50 %+14.03%
106.55 %+19.83%
88.92 %-143.99%
-202.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stille Stock analysis

What does Stille do? Stille AB generates revenue by developing and selling medical equipment through two distinct business lines. The Surgery business area focuses on handcrafted, forged surgical instruments for open surgery, particularly in cardiovascular, reconstructive, and aesthetic plastic surgery. This segment produces essential tools such as scissors, forceps, artery forceps, needle holders, and clamps for medical professionals requiring precision instruments. The second revenue stream comes from the Patient Positioning area, which manufactures specialized procedure-specific tables. These devices are designed for cardiovascular surgery as well as gynecology, urology, and urodynamic examinations. By offering tailored positioning solutions for these specific medical fields, the company supports clinical procedures that require precise patient alignment. The company's operational structure includes wholly owned subsidiaries Stille Surgical Inc. and Stille Incentive AB, which support its manufacturing and distribution efforts. In 2013, the company adjusted its portfolio by selling its Sonesta business unit to ADDvise Lab Solutions publ AB, allowing it to focus on its core surgical and positioning equipment offerings. Stille is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stille stock

FCF Conversion Rate (FCF/EBITDA) of Stille is 27.76 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Stille changed from 101.77 % to 27.76 %, representing a -72.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Stille since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Stille with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Stille

All Key Metrics — Stille